pyruvic acid has been researched along with sorafenib in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gnocchi, D; Kurzyk, A; Lentini, G; Mazzocca, A; Mintrone, A; Sabbà, C | 1 |
1 other study(ies) available for pyruvic acid and sorafenib
| Article | Year |
|---|---|
Inhibition of LPAR6 overcomes sorafenib resistance by switching glycolysis into oxidative phosphorylation in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Glycolysis; Humans; Lactic Acid; Liver Neoplasms; Oxidative Phosphorylation; Pyruvic Acid; Receptors, Lysophosphatidic Acid; Sorafenib | 2022 |